HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT)
Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $51.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 159.01% from the company’s previous close. Several other […]
Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $51.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 159.01% from the company’s previous close. Several other […]
